Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sucrosofate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 6/20 | 0.65 |
| ▸ | FGF2 | P09038 | 5/20 | 0.65 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.36 |
| ▸ | HPSE | Q9Y251 | 12/20 | 0.32 |
| ▸ | VEGFA | P15692 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrosofate SCHEMBL18244210 | 1.00 | FGF1 (0.65) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL16661862 | 0.93 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL18467935 | 0.93 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL16661861 | 0.93 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL145070 | 0.93 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL145069 | 0.93 | FGF1 (0.74) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL18742107 | 0.92 | FGF1 (0.72) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL921799 | 0.92 | FGF1 (0.72) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Sucrosofate SCHEMBL19358882 | 0.90 | FGF1 (0.65) | FGF1FGF2SERPINC1HPSEVEGFA | |
| Water SCHEMBL41379 | 0.83 | FGF1 (0.61) | FGF1FGF2SERPINC1HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4309657-A2 | REMOTE LOADING OF SPARINGLY WATER-SOLUBLE DRUGS INTO LIPOSOMES | Celator Pharmaceuticals, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230390317-A1 | Remote Loading of Sparingly Water-Soluble Drugs Into Lipid Vesicles | Jazz Pharmaceuticals Therapeutics, Inc. | 2023-12-07 | — | — | US | disclosed |
| EP-3922241-B1 | REMOTE LOADING OF SPARINGLY WATER-SOLUBLE DRUGS INTO LIPOSOMES | CELATOR PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4218730-B1 | LIPOSOMES USEFUL FOR DRUG DELIVERY | IPSEN BIOPHARM LTD (GB) | 2023-11-01 | — | — | EP | disclosed |
| EP-4218730-A1 | LIPOSOMES USEFUL FOR DRUG DELIVERY | Ipsen Biopharm Ltd. (GB) | 2023-08-02 | — | — | EP | disclosed |
| US-20230181567-A1 | Liposomes Useful for Drug Delivery | IPSEN BIOPHARM LTD. (GB) | 2023-06-15 | — | — | US | disclosed |
| US-11583544-B2 | Remote loading of sparingly water-soluble drugs into lipid vesicles | CELATOR PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3922241-A1 | REMOTE LOADING OF SPARINGLY WATER-SOLUBLE DRUGS INTO LIPOSOMES | Zoneone Pharma, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-11052079-B2 | Liposomes useful for drug delivery | IPSEN BIOPHARM LTD. | 2021-07-06 | — | — | US | disclosed |
| US-20210137914-A1 | Liposomes Useful for Drug Delivery | IPSEN BIOPHARM LTD. (GB) | 2021-05-13 | — | — | US | disclosed |
| CN-1980637-B | Liposomes for drug delivery | HERMES BIOSCIENCES INC | 2014-02-19 | — | — | CN | disclosed |
| US-20130122081-A1 | LIPOSOMES USEFUL FOR DRUG DELIVERY | IPSEN BIOPHARM LTD. (GB) | 2013-05-16 | — | — | US | disclosed |
| US-8329213-B2 | Liposomes useful for drug delivery | MERRIMACK PHARMACEUTICALS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120171283-A1 | Liposomes Useful for Drug Delivery | IPSEN BIOPHARM LTD. (GB) | 2012-07-05 | — | — | US | disclosed |
| US-8147867-B2 | Liposomes useful for drug delivery | HERMES BIOSCIENCES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| CN-1980637-A | Liposomes for drug delivery | HERMES BIOSCIENCES INC (US) | 2007-06-13 | — | — | CN | disclosed |
| US-20070116753-A1 | Liposomes useful for drug delivery | HERMES BIOSCIENCES, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070110798-A1 | Liposomes useful for drug delivery to the brain | HERMES BIOSCIENCES, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1746976-A1 | LIPOSOMES USEFUL FOR DRUG DELIVERY | Hermes Biosciences, Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005107712-A1 | LIPOSOMES USEFUL FOR DRUG DELIVERY | HERMES BIOSCIENCES, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052079-B2 | Liposomes useful for drug delivery | ABHD16A, LIPA, AGPAT5 | FGF1 4106/4885FGF2 3422/4885SERPINC1 3447/4885 |
| US-20210137914-A1 | Liposomes Useful for Drug Delivery | ABHD16A, LIPA, AGPAT5 | FGF1 4106/4885FGF2 3422/4885SERPINC1 3447/4885 |
| US-20130122081-A1 | LIPOSOMES USEFUL FOR DRUG DELIVERY | ABHD16A, LIPA, AGPAT5 | FGF1 4112/4885FGF2 3425/4885SERPINC1 3475/4885 |
| US-20230181567-A1 | Liposomes Useful for Drug Delivery | ABHD16A, LIPA, AGPAT5 | FGF1 4106/4885FGF2 3422/4885SERPINC1 3447/4885 |
| US-20070116753-A1 | Liposomes useful for drug delivery | ABHD16A, LIPA, AGPAT5 | FGF1 4106/4885FGF2 3422/4885SERPINC1 3447/4885 |
| US-20120171283-A1 | Liposomes Useful for Drug Delivery | ABHD16A, LIPA, AGPAT5 | FGF1 4112/4885FGF2 3425/4885SERPINC1 3475/4885 |
| US-20070110798-A1 | Liposomes useful for drug delivery to the brain | ATP6V1B2, LPCAT3, AGPAT5 | FGF1 3846/4885FGF2 3017/4885SERPINC1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.